Cocrystal Pharma, Inc. (NASDAQ:COCP) Short Interest Up 186.5% in June

Cocrystal Pharma, Inc. (NASDAQ:COCP) was the recipient of a large increase in short interest in the month of June. As of June 15th, there was short interest totaling 410,154 shares, an increase of 186.5% from the May 31st total of 143,168 shares. Based on an average daily trading volume, of 108,694 shares, the days-to-cover ratio is presently 3.8 days. Currently, 4.9% of the shares of the stock are short sold.

Cocrystal Pharma Trading Up 0.5%

Cocrystal Pharma stock traded up $0.01 during midday trading on Friday, reaching $1.01. The company’s stock had a trading volume of 67,851 shares, compared to its average volume of 102,689. The stock has a market cap of $14.00 million, a PE ratio of -1.39 and a beta of 1.42. Cocrystal Pharma has a 52 week low of $0.86 and a 52 week high of $2.67. The business has a 50-day moving average price of $1.19 and a 200-day moving average price of $1.11.

Cocrystal Pharma (NASDAQ:COCP) last posted its quarterly earnings results on Friday, May 15th. The company reported ($0.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.02). The firm had revenue of $0.23 million for the quarter, compared to the consensus estimate of $0.23 million. As a group, research analysts predict that Cocrystal Pharma will post -0.69 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, Weiss Ratings raised shares of Cocrystal Pharma from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, June 8th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, Cocrystal Pharma has a consensus rating of “Sell”.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Cocrystal Pharma stock. DRW Securities LLC bought a new position in shares of Cocrystal Pharma, Inc. (NASDAQ:COCP) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 33,593 shares of the company’s stock, valued at approximately $33,000. DRW Securities LLC owned 0.24% of Cocrystal Pharma at the end of the most recent reporting period. Institutional investors own 6.72% of the company’s stock.

About Cocrystal Pharma

Cocrystal Pharma, Inc (NASDAQ:COCP) is a clinical-stage biotechnology company focused on the discovery and development of novel antiviral therapeutics. Utilizing an integrated structure-guided drug design platform, the company combines x-ray crystallography, computational chemistry and medicinal chemistry to identify and optimize small molecule inhibitors targeting key viral enzymes. This approach is intended to accelerate the progression of lead candidates from discovery through preclinical development.

The company’s pipeline includes multiple preclinical programs aimed at treating respiratory and systemic viral infections.